Adding chemo to Tagrisso slows form of lung cancer

The addition of chemotherapy to Tagrisso (osimertinib) extended median progression-free survival by nearly nine months in EGFR-mutated advanced lung cancer in the FLAURA2 Phase III trial.

This combination reduced the risk of disease progression by 38% versus Tagrisso monotherapy, the current first-line global standard of care.

"With these convincing data, patients may soon have a choice of two highly effective osimertinib-based treatment options in this advanced disease setting"By investigator assessment, the combination extended median progression-free survival (PFS) by 8.8 months versus the AstraZeneca (LSE: AZN) drug alone.